Literature DB >> 19309423

Onychomycosis and diabetes.

S Cathcart1, W Cantrell, B e Elewski.   

Abstract

OBJECTIVE: This study aims to discuss factors specific to diabetics in the diagnosis and treatment of onychomycosis. DISCUSSION: Onychomycosis has the potential to cause severe complications in diabetics and should be treated promptly. The existence of comorbid conditions and potential for drug-drug interactions complicates the selection of an appropriate treatment regimen. The role of Candida in onychomycosis is controversial but may be of increased significance in the diabetic population due to an underlying vulnerability to this organism.
CONCLUSIONS: Terbinafine is an excellent choice in diabetics due to its low risk of drug-drug interaction and proven efficacy against the typical pathogens that cause onychomycosis. Itraconazole, while an effective treatment for onychomycosis, is not a first-choice therapy due to its black-box cardiac warning and numerous drug interactions. Larger studies are needed in diabetics to determine the frequency of candidal nail infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19309423     DOI: 10.1111/j.1468-3083.2009.03225.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  12 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 2.  [Diabetic foot syndrome].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2011-07       Impact factor: 0.751

3.  Preparation, characterization, and in vitro permeation study of terbinafine HCl in poloxamer 407-based thermogelling formulation for topical application.

Authors:  Christel C Müller-Goymann
Journal:  AAPS PharmSciTech       Date:  2011-04-09       Impact factor: 3.246

Review 4.  Onychomycosis nailed.

Authors:  M Leelavathi; Mn Noorlaily
Journal:  Malays Fam Physician       Date:  2014-04-30

5.  Prevalence and Characteristics of Onychomycosis in Patients with Knee Osteoarthritis: A Single-centre Prospective Cross-sectional Study.

Authors:  Soyun Cho; Hanjae Lee; Ji Ye Hwang; Jong Soo Choi; Hyeong Jik Kim; Tae Woo Kim; Seung-Baik Kang
Journal:  Acta Derm Venereol       Date:  2021-08-25       Impact factor: 3.875

6.  Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review.

Authors:  Lisa Matricciani; Kerwin Talbot; Sara Jones
Journal:  J Foot Ankle Res       Date:  2011-12-04       Impact factor: 2.303

7.  Aspergillus species: An emerging pathogen in onychomycosis among diabetics.

Authors:  T M Wijesuriya; J Kottahachchi; T D C P Gunasekara; U Bulugahapitiya; K N P Ranasinghe; S S Neluka Fernando; M M Weerasekara
Journal:  Indian J Endocrinol Metab       Date:  2015 Nov-Dec

8.  Laser therapy for onychomycosis in patients with diabetes at risk for foot complications: study protocol for a randomized, double-blind, controlled trial (LASER-1).

Authors:  Leonie Nijenhuis-Rosien; Nanne Kleefstra; Maurice J Wolfhagen; Klaas H Groenier; Henk J G Bilo; Gijs W D Landman
Journal:  Trials       Date:  2015-03-22       Impact factor: 2.279

9.  Onychomycosis due to nondermatophytic molds.

Authors:  Sung Min Hwang; Moo Kyu Suh; Gyoung Yim Ha
Journal:  Ann Dermatol       Date:  2012-04-26       Impact factor: 1.444

10.  Relationship among Short and Long Term of Hypoinsulinemia-Hyperglycemia, Dermatophytosis, and Immunobiology of Mononuclear Phagocytes.

Authors:  Thais F C Fraga-Silva; Camila M Marchetti; Luiza A N Mimura; Gisele A Locachevic; Márjorie A Golim; James Venturini; Maria S P Arruda
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.